The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification
Sponsor study identifier
observational
2,900
1 country
1
Study Start
February 2006
Actual (reported)Primary Completion
January 2021
Actual (reported)Study Completion
January 2022
Actual (reported)To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2006
Actual (reported)December 16, 2017
Actual (reported)December 20, 2017
Actual (reported)January 2021
Actual (reported)January 2022
Actual (reported)The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk
To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification
per 1 year
Patients who were diagnosed with gastric cancer
Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
Patients who visited gastroenterology department complaining of gastrointestinal symptoms and underwent esophagogastroduodenoscopy (EGD)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 463-707, South Korea
Officials Officials, Officials
Seoul National University Bundang Hospital
2,900 participants (actual enrollment reported by the registry).
First Submitted
December 16, 2017
First Posted
December 20, 2017
Study Start
February 2006
Actual (reported)Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
Contact the study team to confirm eligibility.
Primary Completion
January 2021
Actual (reported)Study Completion
January 2022
Actual (reported)Last Updated
April 13, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: